Merck’s Jay Galeota Joins G&W Laboratories
Executive Summary
Jay Galeota , Merck & Co’s former chief strategy and business development officer and president of emerging businesses, has been appointed president and chief operating officer of G&W Laboratories. He will take over the role from current president Kurt Orlofski, who will assume the newly created position of president of generics. Prior to joining G&W, Galeota spent 28 years at Merck, working both in the US and globally and helping to establish the Merck Global Health Fund and Innovative Venture Group, as well as leading the development and launching of Merck’s top-grossing products, Januvia and Janumet.
You may also be interested in...
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements
Recent moves in the industry include C-suite shuffle at Brainstorm Cell Therapeutics and new CFOs at Faron Pharmaceuticals and Foghorn Therapeutics, among others.
Pipeline Watch: Six Approvals And 15 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.